Company news

Theralase Technologies Inc. news in 2023

Theralase Technologies Inc.'s news releases, calls and decks from 2023, newest first.

View company

Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA

December 4, 2023

Theralase Release's 3Q2023 Interim Financial Statements

November 29, 2023

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

November 29, 2023

Theralase(R) Announces Brokered LIFE Financing

October 23, 2023

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

October 23, 2023

Theralase(R) Files US Patent for Enhanced Immunotherapy

October 5, 2023

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

September 29, 2023

Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer

September 27, 2023

Theralase(R) Grants Stock Options

September 21, 2023

Theralase(R) Closes Private Placement Equity Financing

September 7, 2023

Theralase Release's 2Q2023 Interim Financial Statements

August 29, 2023

Theralase(R) Closes Non-Brokered Private Placement Equity Financing

June 30, 2023

Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

June 13, 2023

Theralase(R) Announces Appointment of New Independent Director

June 6, 2023

Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements

May 30, 2023

Theralase(R) Releases 1Q2023 Interim Financial Statements

May 30, 2023

Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer

May 24, 2023

Theralase Provides Update on Phase II Bladder Cancer Study

May 10, 2023

Decks in 2023